Veterinary Monoclonal Antibodies Market Revenue to Attain USD 5.62 Bn by 2035

Published: 12 Mar 2026

Author: Precedence Research

Share:

Veterinary Monoclonal Antibodies Market Revenue and Trends 2026 to 2035

The global veterinary monoclonal antibodies market revenue surpassed USD 1.74 billion in 2025 and is predicted to attain around USD 5.62 billion by 2035, growing at a CAGR of 12.44%. The growth of the market is driven by rising pet ownership, innovation in targeted biologics, and the expansion of pet insurance.

What is the Significance of the Veterinary Monoclonal Antibodies Market?

Veterinary monoclonal antibodies are defined as a transformative key in animal healthcare due to their innovation in therapeutics for chronic diseases in animals that focus on reducing side effects. The rising economic growth and rising platforms for sustainable veterinary care solutions are driving the market. Additionally, government initiatives and public support in veterinary care are stimulating market expansion.

Segment Insights

• By animal type, the dogs segment contributed the largest market share of 61% in 2025, driven by the adoption of lokivetmab for atopic dermatitis and bedinvetmab for osteoarthritis. The growth is fueled by the aging dog population and the availability of pet insurance, which improves access to premium therapies that are pushing the market towards biopharmaceutical innovation in animal healthcare
• By product type, the anti-IL-31 monoclonal antibodies segment held the biggest market share of 34% in 2025, driven by a focus on allergic skin disease management. Additionally, there is a strong focus on species-specific innovations and computational protein design, which supports segmental dominance.
• By therapy area, the dermatology (Atopic Dermatitis) segment contributed the largest market share of 42% in 2025. It is redefining atopic dermatitis treatment through biologics like lokivetmab that target IL-31, offering precise, systemic alternatives that avoid collateral damage and immunosuppression. Innovation aims at bispecific antibodies and recombinant proteins for long-term immune modulation in allergic skin disease, also driving segmental growth.
• By route of optimization, the injectable monoclonal antibodies segment held the highest share of approximately 78% in 2025, serving as a biological intervention, ensuring systemic delivery. They provide sustained release effects, reduce owner non-compliance in daily oral dosing, and build a professional-client bond. Additionally, Current R&D focuses on low-volume, stable formulations to enhance longevity and injection-site sensitivity for next-generation immunotherapies.
• By end-user, the veterinary hospitals segment maintains its dominance by holding the largest share of around 58% in 2025. These facilities offer the controlled environment needed for cold chain storage and administration, ensuring compliance. This segment employs advanced serology to justify treatment use.  It is a clinical model for maintaining biochemical integrity, and this centralization supports precision medicine.

Regional Insights

North America dominated the veterinary monoclonal antibodies market by holding around 43% share in 2025. This is mainly due to the advanced veterinary infrastructure and commercialization of biologics. The high pet ownership and income levels offer safety and long-acting efficiency. The region’s transition toward precision biopharmaceuticals fosters early adoption of innovative therapies.

Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period, fueled by biotechnological integration and rising disposable incomes. Pet humanization and strategic domestic partnerships for species-specific biologics are driving the innovation that focuses on low-toxicity solutions that are solidifying the Asia Pacific's position in advanced clinical infrastructure.

Veterinary Monoclonal Antibodies Market Coverage

Recent Development

• In January 2025, The Absci Corporation and Invetx announced a strategic partnership to use generative AI for creating animal health drugs. The focus is to make a half-life extension platform for animal health applications.(Source: https://markets.financialcontent.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7970

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344